The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > BUSINESS
BUSINESS
- Novartis Files Combination Drug for Parkinson’s Disease in Japan
June 28, 2013
- Bayer Yakuhin to Shift Resources to Innovative New Drugs: President Brunn
June 28, 2013
- Reasons for Doctors’ Reluctance to Generic Name Prescribing is Time and Effort: CareNet Survey
June 28, 2013
- Tsumura Reports Record Profits through Intensified MR Activities to Educate Doctors about Kampo Medicine
June 28, 2013
- Astellas Begins Global PIII Study of Cytomegalovirus Vaccine
June 27, 2013
- Shionogi Establishes New Chinese Subsidiary
June 27, 2013
- Astellas, Cytokinetics Agree to Develop, Commercialize Skeletal Muscle Activators
June 27, 2013
- Takeda Files BLA for CD, UC Treatment in US
June 27, 2013
- Eisai Launches Aricept Dry Syrup
June 26, 2013
- Eisai to Suspend Sales of Future Mainstay Antiepileptic Drug in Germany
June 26, 2013
- Success in Emerging Markets Key for Drug Makers’ Growth: IMS Japan Senior Principal
June 26, 2013
- Myelofibrosis Treatment Jakavi Reduced Risk of Death by 52% in 3-Year Follow-up Study: Novartis AG
June 26, 2013
- Anticancer Agent Xtandi Receives Approval Also in Europe: Astellas
June 26, 2013
- Filgrastim Biosimilars: Overseas Track Record vs. “Purely Made-in-Japan” Label
June 25, 2013
- Novartis AG Probing 10-Plus Years of Documents, Emails over Diovan Papers
June 25, 2013
- Taiho to Launch New Formulation TS-1, World’s 1st Anticancer OD Tablets
June 25, 2013
- UMN, API, Yakult Officially Agree on Joint Biosimilar Business
June 24, 2013
- Toho Holdings Targets 26.1 Billion Yen Operating Profit in FY2015
June 24, 2013
- Volibris Receives Orphan Drug Designation for Indication of CTEPH in Japan: GSK
June 24, 2013
- Kowa, Sanofi File NDAs for SGLT-2 Inhibitor Tofogliflozin in Japan
June 24, 2013
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…